Merck's Patent Cliff Fears Are Overblown: A 15% Upside Opportunity
By stockpickr AI | March 4, 2026 | 10 min read
Investment Summary
Merck & Co. is currently undervalued based on a DCF analysis, suggesting that the market is over-discounting the patent cliff risk for its oncology segment.
Investment Recommendation
Buy
Fair Value: $118.00
Current Price: $102.50
Upside/Downside: +15%
Our DCF model indicates an intrinsic value higher than the current market price, driven by steady cash flow growth in core oncology segments. Despite patent risks, the current valuation fails to reflect the potential of the pipeline.
Key Metrics
- Market Cap: $259B
- P/E Ratio: 16.2x
- Forward P/E: 12.8x
- Revenue Growth (YoY): 7%
- Net Margin: 12%
- ROE: 32%
- Debt/Equity: 1.15
- Dividend Yield: 3.1%
Strengths
- Keytruda maintains market dominance as a foundational immunotherapy with over $25 billion in annual revenue.
- Strong Animal Health segment provides consistent, non-cyclical revenue growth with high margins.
- Robust R&D pipeline with over 80 clinical programs in late-stage development.
- Strong free cash flow generation allowing for consistent dividend growth and share buybacks.
Risk Factors
- High revenue concentration risk, with Keytruda accounting for roughly 40% of total sales.
- Significant patent expirations starting in 2028 create a major revenue cliff.
- Potential regulatory headwinds from the Inflation Reduction Act regarding drug price negotiations.